EANS-Adhoc: SYGNIS Pharma AG / SYGNIS announces Management Board changes

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Board of Directors (Appointments and Changes)/C.E.O. Interviews
25.03.2013

SYGNIS announces Management Board changes

Heidelberg, March 25, 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard), today announced that Chief Financial
Officer (CFO) and member of the Management Board, Peter Willinger
will be stepping down effective 31 March 2013 for personal reasons.
He is leaving the company by mutual agreement with the Supervisory
Board. Pilar de la Huerta, the company's CEO since 2012 and a former
senior manager and CFO at Zeltia, S.A., the largest Spanish quoted
biotech company, will now hold both positions, CFO and CEO.

**** end of ad hoc ****

For further information please contact:

SYGNIS Pharma AG
Pilar de la Huerta

CEO/CFO
Tel: +34-918063089
Email: pdelahuerta@sygnis.es

### Disclaimer

This publication is intended for information only and constitutes
neither an offer to sell nor an invitation to buy securities. Some
statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as
forward-looking, i.e. not definite. Such statements are mainly
predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1RFM03
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English